Abstract
Novel methods for the treatment of inflammatory and autoimmune diseases comprising the administration of salt-inducible kinase inhibitors are claimed. One novel inhibitor (HG-9-91-01) and the use of 2,4-diaminopyrimidine and 2,6-diaminopyrimidine derivatives are claimed. The use of such inhibitors upregulates the level of the anti-inflammatory cytokine IL-10 in macrophages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
